Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study

被引：95

作者：

Kim, Kihyun ^{[1
]}

Lee, Jae Hoon ^{[2
]}

Kim, Jin Seok ^{[3
]}

Min, Chang Ki ^{[4
]}

Yoon, Sung Soo ^{[5
]}

Shimizu, Kazuyuki ^{[6
]}

Chou, Takaaki ^{[7
]}

Kosugi, Hiroshi ^{[8
]}

Suzuki, Kenshi ^{[9
]}

Chen, Wenming ^{[10
]}

Hou, Jian ^{[11
]}

Lu, Jin ^{[12
]}

Huang, Xiao-Jun ^{[12
]}

Huang, Shang-Yi ^{[13
]}

Chng, Wee Joo ^{[14
]}

Tan, Daryl ^{[15
,16
]}

Teoh, Gerrard ^{[17
]}

Chim, Chor Sang ^{[18
]}

Nawarawong, Weerasak ^{[19
]}

Siritanaratkul, Noppadol ^{[20
]}

Durie, Brian G. ^{[21
]}

机构：

[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul, South Korea

[2] Gachon Univ, Gil Med Ctr, Dept Internal Med, Div Hematol Oncol, Inchon 405220, South Korea

[3] Yonsei Univ, Coll Med, Severance Hosp, Div Hematol,Dept Internal Med, Seoul, South Korea

[4] Catholic Univ Korea, Seoul St Marys Hosp, Dept Internal Med, Seoul, South Korea

[5] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea

[6] Tokai Cent Hosp, Dept Hematol, Kakamigahara, Japan

[7] Niigata Canc Ctr Hosp, Dept Internal Med, Niigata, Japan

[8] Ogaki Municipal Hosp, Dept Hematol, Ogaki, Japan

[9] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan

[10] Capital Med Univ, Beijing Chaoyang Hosp, Dept Hematol, Beijing, Peoples R China

[11] Chang Zheng Hosp, Dept Hematol, Myeloma & Lymphoma Ctr, Shanghai, Peoples R China

[12] Peking Univ, Inst Hematol, Peking Univ Peoples Hosp, Dept Hematol, Beijing 100871, Peoples R China

[13] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan

[14] Natl Univ Hlth Syst, Natl Univ Canc Inst Singapore, Dept Haematol Oncol, Singapore, Singapore

[15] Raffles Hosp, Raffles Canc Ctr, Dept Internal Med, Singapore, Singapore

[16] Singapore Gen Hosp, Dept Hematol, Dept Med, Singapore, Singapore

[17] Novena Med Ctr, Gerrard Teoh Hematol & Med Clin, Singapore, Singapore

[18] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China

[19] Chiang Mai Med Sch, Dept Med, Maung, Thailand

[20] Siriraj Hosp, Dept Med, Div Hematol, Bangkok, Thailand

[21] Cedars Sinai Comprehens Canc Ctr, Dept Hematol, Los Angeles, CA USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2014年 / 89卷 / 07期

关键词：

CHRONIC LYMPHOCYTIC-LEUKEMIA; COMPLEMENT-DEPENDENT CYTOTOXICITY; RANDOMIZED PHASE-3 TRIAL; COATED TARGET-CELLS; HIGH-RISK; RICHTER SYNDROME; NK ACTIVATION; GENE MUTATION; CD20; LOSS; ALEMTUZUMAB;

D O I：

10.1002/ajh.23731

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The incidence of multiple myeloma (MM) is known to be variable according to ethnicity. However, the differences in clinical characteristics between ethnic groups are not well-defined. In Asian countries, although the incidence of MM has been lower than that of Western countries, there is growing evidence that MM is increasing rapidly. The Asian Myeloma Network decided to initiate the first multinational project to describe the clinical characteristics of MM and the clinical practices in Asia. Data were retrospectively collected from 23 centers in 7 countries and regions. The clinical characteristics at diagnosis, survival rates and initial treatment of 3,405 symptomatic MM patients were described. Median age was 62 years (range, 19-106), with 55.6% of being male. Median overall survival (OS) was 47 months (95% CI 44.0-50.0). Stem cell transplantation was performed in 666 patients who showed better survival rates (79 vs. 41 months, P < 0.001). The first-line treatments of 2,970 patients were analyzed. The overall response rate was 71% including very good partial response or better in 31% of the 2,660 patients those were able to be evaluated. New drugs including bortezomib, thalidomide, and lenalidomide were used in 36% of 2,970 patients and affected OS when used as a first-line treatment. (C) 2014 Wiley Periodicals, Inc.

引用

页码：751 / 765

页数：15

共 58 条

[1]

[Anonymous], 2008, WHO CLASSIFICATION T

[2] Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia [J].

Aue, Georg ;

Lindorfer, Margaret A. ;

Beum, Paul V. ;

Pawluczkowycz, Andrew W. ;

Vire, Berengere ;

Hughes, Thomas ;

Taylor, Ronald P. ;

Wiestner, Adrian .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (02) :329-332

[3] Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia [J].

Badoux, Xavier C. ;

Keating, Michael J. ;

Wang, Xuemei ;

O'Brien, Susan M. ;

Ferrajoli, Alessandra ;

Faderl, Stefan ;

Burger, Jan ;

Koller, Charles ;

Lerner, Susan ;

Kantarjian, Hagop ;

Wierda, William G. .

BLOOD, 2011, 118 (08) :2085-2093

[4] Induced Resistance to Ofatumumab-Mediated Cell Clearance Mechanisms, Including Complement-Dependent Cytotoxicity, in Chronic Lymphocytic Leukemia [J].

Baig, Nisar A. ;

Taylor, Ronald P. ;

Lindorfer, Margaret A. ;

Church, Amy K. ;

LaPlant, Betsy R. ;

Pettinger, Adam M. ;

Shanafelt, Tait D. ;

Nowakowski, Grzegorz S. ;

Zent, Clive S. .

JOURNAL OF IMMUNOLOGY, 2014, 192 (04) :1620-1629

[5] Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement [J].

Baig, Nisar A. ;

Taylor, Ronald P. ;

Lindorfer, Margaret A. ;

Church, Amy K. ;

Laplant, Betsy R. ;

Pavey, Emily S. ;

Nowakowski, Grzegorz S. ;

Zent, Clive S. .

LEUKEMIA & LYMPHOMA, 2012, 53 (11) :2218-2227

[6] The shaving reaction: Rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes [J].

Beum, PV ;

Kennedy, AD ;

Williams, ME ;

Lindorfer, MA ;

Taylor, RP .

JOURNAL OF IMMUNOLOGY, 2006, 176 (04) :2600-2609

[7] Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients [J].

Beurskens, Frank J. ;

Lindorfer, Margaret A. ;

Farooqui, Mohammed ;

Beum, Paul V. ;

Engelberts, Patrick ;

Mackus, Wendy J. M. ;

Parren, Paul W. H. I. ;

Wiestner, Adrian ;

Taylor, Ronald P. .

JOURNAL OF IMMUNOLOGY, 2012, 188 (07) :3532-3541

[8] Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice [J].

Boross, Peter ;

Jansen, J. H. Marco ;

Pastula, Agnieszka ;

van der Poel, Cees E. ;

Leusen, Jeanette H. W. .

IMMUNOLOGY LETTERS, 2012, 143 (01) :44-52

[9] CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells [J].

Bowles, JA ;

Weiner, GJ .

JOURNAL OF IMMUNOLOGICAL METHODS, 2005, 304 (1-2) :88-99

[10] Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia [J].

Byrd, John C. ;

Furman, Richard R. ;

Coutre, Steven E. ;

Flinn, Ian W. ;

Burger, Jan A. ;

Blum, Kristie A. ;

Grant, Barbara ;

Sharman, Jeff P. ;

Coleman, Morton ;

Wierda, William G. ;

Jones, Jeffrey A. ;

Zhao, Weiqiang ;

Heerema, Nyla A. ;

Johnson, Amy J. ;

Sukbuntherng, Juthamas ;

Chang, Betty Y. ;

Clow, Fong ;

Hedrick, Eric ;

Buggy, Joseph J. ;

James, Danelle F. ;

O'Brien, Susan .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (01) :32-42

← 1 2 3 4 5 6 →